Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B

Clinical Microbiology and Infection

Volumn 20, Issue 11, 2014, Pages 1173-1180

  Seto, W K ^a   Wong, D K H ^a   Fung, J ^a   Huang, F Y ^a   Liu, K S H ^a   Lai, C L ^a   Yuen, M F ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HBV; HBcrAg; HBsAg; HQ HBsAg; Serology

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; ENZYME IMMUNOASSAY; FALSE NEGATIVE RESULT; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HISTORY; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRAL CLEARANCE; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; VERY ELDERLY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

EID: 84917675883     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12739     Document Type: Article

References (30)

1. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61.
2. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
3. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Brunetto MR, Oliveri F, Colombatto P et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype d carriers. Gastroenterology 2010; 139: 483-490.
5. Tseng TC, Liu CJ, Yang HC et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-450.
6. Tseng TC, Liu CJ, Yang HC et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.
7. Seto WK, Wong DK, Fung J et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One 2012; 7: e43087.
8. Seto WK, Wong DK, Fung J et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-819.
9. Yuen MF, Wong DK, Fung J et al. HBsAg seroclearance in chronic hepatitis B in asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199.
10. Weber B. Genetic variability of the s gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32: 102-112.
11. Matsubara N, Kusano O, Sugamata Y et al. A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection. Transfusion 2009; 49: 585-595.
12. Shinkai N, Matsuura K, Sugauchi F et al. Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. J Clin Microbiol 2013; 51: 3484-3491.
13. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81: 27-33.
14. Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45: 3942-3947.
15. Kumada T, Toyoda H, Tada T et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 427-433.
16. Seto WK, Tanaka Y, Wong DK et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 2013; 7: 98-105.
17. Sonneveld MJ, Hansen BE, Piratvisuth T et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872-880.
18. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-931.
19. Seto WK, Liu K, Wong DK et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 59: 709-716.
20. Thompson AJ, Nguyen T, Iser D et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
21. Jaroszewicz J, Calle Serrano B, Wursthorn K et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a european perspective. J Hepatol 2010; 52: 514-522.
22. Hosaka T, Suzuki F, Kobayashi M et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-1470.
23. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88.
24. Yang HI, Yuen MF, Chan HL et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (reach-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574.
25. Simonetti J, Bulkow L, McMahon BJ et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-1537.
26. Tai DI, Tsay PK, Chen WT, Chu CM, Liaw YF. Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. Am J Gastroenterol 2010; 105: 1102-1109.
27. Wong DK, Huang FY, Lai CL et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-836.
28. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
29. Vigano M, Vener C, Lampertico P et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic sct. Bone Marrow Transplant 2011; 46: 125-131.
30. Kim GA, Lim YS, An J et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014; 63: 1325-1332.